1. Two doses of the Pfizer-BioNTech BNT162b2 vaccine were linked to high immediate protection again severe acute respiratory syndrome coronary virus 2 (SARS-CoV02) infection, which waned after 6 months post-immunization. 2. Immunity acquired from infection boosted with subsequent vaccination remained high more than 1 tear after the initial infection. Evidence Rating Level: 2 (Good) Study […]
The third dose of AstraZeneca COVID-19 vaccine is effective against symptomatic disease and hospitalisation, offering protection comparable to a booster shot of the Pfizer preventive, according to a study conducted in the UK.
Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.